Ani Pharmaceuticals, Inc. · NASDAQ:ANIP

Ani Pharmaceuticals — Jefferies Healthcare Conference June 2021

14 slides from Ani Pharmaceuticals's conference presentation, Jun 4, 2021

  1. Slide 1: Jefferies Healthcare Conference June 2021

    © 2021 ANI Pharmaceuticals, Inc. 1 © 2021 ANI Pharmaceuticals, Inc. 1 Jefferies Healthcare Conference June 2021 Jefferies Healthcare Conference

  2. Slide 2: Disclaimer

    © 2021 ANI Pharmaceuticals, Inc. 2 Disclaimer Cautionary Note Regarding Forward - Looking Statements This presentation contemplates the acquisition by ANI Pharmaceuticals, Inc (“ANI” or the “Company”) of Novitium Pharma, LLC (“ Novitium ”) and contains forward - looking statements, including informa

  3. Slide 3: Company Snapshot

    © 2021 ANI Pharmaceuticals, Inc. 3 Company Snapshot Poised for sustainable growth US - focused diversified biopharma with Rare Disease, Generics, Established Brands and CDMO businesses 30% Revenues 26% Gross Profit Strong CAGR growth 2014 to 2020*: Proven acquirer of branded and generic products • C

  4. Slide 4: Strong and Growing U.S.-Focused and Diversified BioPharma Company

    © 2021 ANI Pharmaceuticals, Inc. 4 Strong and Growing U.S. - Focused and Diversified BioPharma Company Revenues (2020) (1) 55 Generic Products 15 Branded Products 6.4 Largest Product’s Percentage of Total Revenue $220.4MM PF 2020 Revenue $75.6MM PF 2020 Adjusted EBITDA (2) 34.3% PF 2020 Adjusted EBI

  5. Slide 5: Proven Strong Growth Profile

    © 2021 ANI Pharmaceuticals, Inc. 5 Proven Strong Growth Profile $208 $53 $12 $56 $76 $129 $177 $202 $207 $274 2014 2015 2016 2017 2018 2019 2020 Revenues $126 $38 $11 $45 $64 $86 $108 $134 $143 $175 2014 2015 2016 2017 2018 2019 2020 Gross Profit ANI Novitium PharmaDerm ANI Novitium PharmaDerm

  6. Slide 6: Strong Business Development Engine to Fuel Growth

    © 2021 ANI Pharmaceuticals, Inc. 6 Strong Business Development Engine to Fuel Growth Brands – 9 Deals Class Seller Products 2018 AZ Atacand & Atacand HCT Casodex & Arimidex 2017 Cranford Inderal XL Innopran XL 2016 Akrimax Inderal LA/Prop ER 2016 Merck Cortrophin 2014 Shire Vancocin assests Noven Li

  7. Slide 7: Four Pillars to Drive Sustainable Growth

    © 2021 ANI Pharmaceuticals, Inc. 7 Four Pillars to Drive Sustainable Growth Build a successful Cortrophin franchise Strengthen Generics Business with enhanced development capability and increased focus on niche opportunities Maximize value from Established Brands through innovative access and GTM st

  8. Slide 8: CORTROPHIN GEL: Transformational opportunity

    © 2021 ANI Pharmaceuticals, Inc. 8 CORTROPHIN GEL: Transformational opportunity 250 237 228 181 173 168 156 148 142 55 52 50 51 49 47 10 10 9 0 100 200 300 400 500 600 700 800 2021 2022 2023 Other Nephrological Desorders Arthritis Multiple Sclerosis Polymyositis & Dermatomy ositis Epilepsy (Infantil

  9. Slide 9: Novitium acquisition: adds best-in-class R&D engine with Generics and 505(b)(2) capabilities

    © 2021 ANI Pharmaceuticals, Inc. 9 Novitium acquisition: adds best - in - class R&D engine with Generics and 505(b)(2) capabilities 9 14 7 14 16 2017 2018 2019 2020 2021 Annual ANDA Filling (1) 4 13 6 25 2018 2019 2020 2021/2022 Annual Product Launches (1) Actual Expected Average filing to approval

  10. Slide 10: Expanding Established Brands Portfolio Products: Derm Acquisition

    © 2021 ANI Pharmaceuticals, Inc. 10 Expanding Established Brands Portfolio Products: Derm Acquisition Acquired Products Key Deal Characteristics Favorable gross margin profile Purchase includes up to three years of inventory Transfer manufacturing in house Ability to leverage existing go - to - mark

  11. Slide 11: Significant North American Manufacturing Footprint with ample capacity and excellent GMP track record

    © 2021 ANI Pharmaceuticals, Inc. 11 Significant North American Manufacturing Footprint with ample capacity and excellent GMP track record GMP • Manufacturing, packaging, warehouse • Schedule CII vault & CIII cage space • Lab space - R&D/analytical testing • Solutions, suspensions, topicals , tablets

  12. Slide 12: Executive Leadership Team with Broad Industry Expertise

    © 2021 ANI Pharmaceuticals, Inc. 12 Executive Leadership Team with Broad Industry Expertise Nikhil Lalwani President & Chief Executive Officer ‒ 20+ years leadership experience in pharmaceuticals and healthcare ‒ Proven track record of developing and executing multi - year strategic growth plans Ste

  13. Slide 13: Thank You!

    © 2021 ANI Pharmaceuticals, Inc. 13 © 2021 ANI Pharmaceuticals, Inc. 13 Thank You!

  14. Slide 14: Appendix: Adjusted non-GAAP EBITDA Calculation and US GAAP to Non-GAAP Reconciliation

    © 2021 ANI Pharmaceuticals, Inc. 14 Appendix ANI Pharmaceuticals, Inc. and Subsidiaries Adjusted non - GAAP EBITDA Calculation and US GAAP to Non - GAAP Reconciliation (unaudited, in thousands) Year Ended December 31, 2020 Net (Loss)/Income $ (22,548 ) Add/(Subtract): Interest expense, net 9,452 Oth

ANI Pharmaceuticals — Jefferies Healthcare Conference June 2021 on 6ix